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Abstract
Background: Transforming growth factor (TGF)-b plays a dual role during mammary gland development and
tumorigenesis and has been shown to stimulate epithelial-mesenchymal transition (EMT) as well as cellular
migration. The Wnt/b-catenin pathway is also implicated in EMT and inappropriate activation of the Wnt/b-catenin
signaling pathway leads to the development of several human cancers, including breast cancer. Secreted frizzled-
related protein 1 (SFRP1) antagonizes this pathway and loss of SFRP1 expression is frequently observed in breast
tumors and breast cancer cell lines. We previously showed that when SFRP1 is knocked down in immortalized
non-malignant mammary epithelial cells, the cells (TERT-siSFRP1) acquire characteristics associated with breast
tumor initiating cells. The phenotypic and genotypic changes that occur in response to SFRP1 loss are consistent
with EMT, including a substantial increase in the expression of ZEB2. Considering that ZEB2 has been shown to
interact with mediators of TGF-b signaling, we sought to determine whether TGF-b signaling is altered in TERT-
siSFRP1 cells.
Methods: Luciferase reporter assays and real-time PCR analysis were employed to measure TGF-b transcriptional
targets. Western blot analysis was used to evaluate TGF-b-mediated ERK1/2 phosphorylation. Migration chamber
assays were utilized to quantify cellular migration. TERT-siSFRP1 cells were transfected with Stealth RNAi™ siRNA in
order to knock-down the expression of ZEB2.
Results: TERT-siSFRP1 cells exhibit a significant increase in both TGF-b-mediated luciferase activity as well as TGF-b
transcriptional targets, including Integrin b3 and PAI-1. Phosphorylation of ERK1/2 is increased in TERT-siSFRP1 cells
in response to enhanced TGF-b signaling. Furthermore, when the TGF-b pathway is blocked with a TGF-bR
antagonist (LY364947), cellular migration is significantly hindered. Finally, we found that when ZEB2 is knocked-
down, there is a significant reduction in the expression of exogeneous and endogenous TGF-b transcriptional
targets and cellular migration is impeded.
Conclusions: We demonstrate that down-regulation of SFRP1 renders mammary epithelial cells more sensitive to
TGF-b signaling which can be partially ameliorated by blocking the expression of ZEB2.
Background
Breast cancer is the most frequently occurring cancer in
women and between 12% and 13% of women will
develop invasive breast cancer over the course of their
lifetime. Cancer results from cellular mutations that
enhance proliferation, decrease tumor suppressive sig-
nals, and decrease programmed cell death; and from cel-
lular alterations that enhance angiogenesis and
metastasis [1]. Notably, metastasis is the most deadly
aspect of breast cancer and takes place when invasive
epithelial cells in a primary tumor leave their site of ori-
gin, digest and break through the extracellular matrix,
migrate into blood vessels, and invade secondary sites.
Epithelial-mesenchymal transition (EMT) is a process
whereby epithelial cells lose polarity as well as cell-cell
contacts and undergo a dramatic remodeling of the
cytoskeleton resulting in a highly motile mesenchymal
morphology. Inappropriate reactivation of EMT is impli-
cated in the conversion of early stage breast tumors into
invasive malignancies. Unfortunately, the molecular
mechanisms by which EMT mediates the initiation of
breast cancer metastasis remain poorly understood.
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tional cytokine that regulates a variety of physiological
processes and also plays a dual role during mammary
gland development and tumorigenesis. TGF-b signaling
is manifested by way of TGF-b receptor activation and
the canonical pathway involves the subsequent phosphor-
ylation of receptor-associated Smad2 and Smad3 proteins
which form complexes with Smad4. These activated
Smad complexes accumulate in the nucleus where, along
with co-activators and cell-specific DNA-binding factors,
they regulate gene expression. In early stage breast malig-
nancies, TGF-b functions as a powerful tumor suppressor
by blocking cell cycle progression, but TGF-b signaling
can become deregulated during mammary tumorigenesis
[2,3]. The neoplastic tumor cell environment ultimately
transforms TGF-b into an oncogenic cytokine which
actively contributes to the acquisition and development
of metastatic phenotypes in part through its ability to sti-
mulate EMT and cellular migration [4-7].
Similar to the TGF-b pathway, the Wnt/b-catenin
pathway is also implicated in EMT and epithelial plasti-
city during development and cancer. Wnt ligands acti-
vate the Wnt/b-catenin signaling pathway by binding to
receptors comprised of Frizzled proteins in conjunction
with one of the LDL receptor-related proteins LRP5 or
LRP6. Receptor activation results in the ability of a cyto-
plasmic protein, Dsh, to dissociate and inactivate a mul-
tiprotein complex that includes APC, Axin, and GSK3b.
As a result, b-catenin is free to accumulate in the
nucleus where it forms a complex with the TCF/
LEF1 family of HMG box transcription factors and sti-
mulates the expression of specific target genes. Inap-
propriate activation of the Wnt/b-catenin pathway,
which results from mutations in several downstream
genes, contributes to the genesis of a wide range of
human cancers [8]. However, such mutations are rarely
observed in breast cancer despite the finding that
b-catenin is stabilized and Wnt signaling is activated in
a majority of human breast tumors [9]. In addition,
aberrantly activated Wnt signaling leads to inappropriate
mammary gland development and mammary tumorigen-
esis in mice [10].
Secreted frizzled-related protein-1 (SFRP1) is a power-
ful Wnt signaling antagonist that contains a cysteine-
rich domain that is homologous to the Wnt-binding
domain of frizzled receptor proteins [11]. Since
SFRP1 lacks a transmembrane domain, it is free to
remain in the extracellular compartment and block
Wnt/b-catenin signaling by binding to Wnt ligands and
preventing ligand-receptor interactions [12]. Loss of
SFRP1 expression is found in a multitude of cancers
including breast cancer [13-15].
When SFRP1 is knocked down in immortalized non-
malignant mammary epithelial cells, the cells (TERT-
siSFRP1) exhibit a malignant phenotype which resembles
the characteristics observed in metastatic breast cancer
cells [16]. Interestingly, the phenotypic and genotypic
changes that occur in response to SFRP1 loss are consis-
tent with EMT. Among the EMT associated genes ana-
lyzed, loss of SFRP1 resulted in a drastic increase in the
expression of ZEB2. Originally, ZEB2 was named Smad
interacting protein 1 (SIP1) due to it’s ability to act in a
ligand-dependent fashion with receptor-activated Smads
and mediate TGF-b signaling [17]. More recently, studies
have revealed that ZEB2 is characterized by N-terminal
and C-terminal zinc-finger clusters that can regulate the
transcription of EMT markers by binding to 5’-CACCT
sequences located in various gene promoters [18]. The
work described here was initiated to investigate whether
the TGF-b signaling pathway is affected by SFRP1 loss.
We demonstrate that down-regulation of SFRP1 renders
mammary epithelial cells more sensitive to TGF-b signal-
ing which can be partially ameliorated by blocking the
expression of ZEB2.
Methods
Cell Culture and Treatments
The 76N TERT cell line (obtained from Dr. Vimla
Band) were stably transfected with either pSUPER.retro
(TERT-pSUPER) or siSFRP1-PSUPER.retro (TERT-
siSFRP1) as previously described [16]. Cells were routi-
nely cultivated at 37°C in 5% CO2 and maintained in
DMEM/F12 (GIBCO, Grand Island, NY) and the follow-
ing components from GIBCO: 1% FBS, 1X Antibiotic-
Antimycotic (100X), and 20 μg/mL Gentamycin. The
following components from Sigma (St Louis, MO) were
also used: 50 μM L(+)-Ascorbic acid sodium salt, 1ng/
ml Cholera Toxin Vibrio, 12.5 ng/ml Epidermal Growth
Factor murine submaxillary, 2 nM b-Estradiol, 0.1 mM
Ethanolamine, 1 μg/ml Hydrocortisone-Water Soluble,
1 μg/ml human Insulin solution, 0.1 mM O-Phosphory-
lethanolamine, 35 μg/ml bovine pituitary extract, 15 nM
Sodium selenite, 10 μg/ml human apo-Transferrin, and
10 nM 3,3’,5-Triiodo-L-thyronine sodium salt. Cells
were plated in 6-well plates (for RNA isolation) and
10 cm dishes (for protein isolation) and allowed to
attach overnight. The following day, media was changed
to contain vehicle (0.1% BSA/4 mM HCl), 2.5 ng/ml
TGF-b1 (Sigma), vehicle (DMSO), 5 μM UO126, and/or
10 μM LY364947 (sigma). For ZEB2 knock down stu-
dies, 62.5 nM ZEB2 Stealth RNAi™ siRNA (Invitrogen)
was transfected into cells using Lipofectamine™
2000 (Invitrogen).
Luciferase Assay
A total of 1 × 10
5 cells/well were plated in 24 well plates
and were transfected the following day with 0.8 μg
CAGA-Luc and 0.08 μg pRL-CMV using lipofectamine
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media was removed and replaced with treatment media
[either vehicle (0.1% BSA/4 mM HCl) or 2.5 ng/ml
TGF-b1]. Twenty-four hours after treatment, cells were
washed with 1X PBS and lysed using passive lysis buffer
(Promega). Luciferase activity was detected using the
Dual-Luciferase
® reporter assay system (Promega)
according to the manufacture’s instructions and the light
output was measured with a luminometer (TD 20/20
Luminometer, Turner Biosystems, Sunnyvale, CA).
RNA Isolation and Real-Time PCR
Total RNA was extracted from treated cells using an
acid-phenol extraction procedure [19], according to the
manufacturer’s instructions (Trizol, Invitrogen, Carlsbad,
CA). Relative levels of mRNA were determined by quan-
titative real-time PCR using the Mx3005P™ real time
PCR system (Stratagene, La Jolla, CA) and all values
were normalized to the amplification of b-Actin. The
PCR primer sequences used are as follows: TGF-
b2f o r w a r d :5 ’- CCAAAGGGTACAATGCCAAC -3’,
TGF-b2 reverse: 5’- CAGATGCTTCTGGATTTATGGT
ATT-3’;S i x 1f o r w a r d :5 ’- ACCGGAGGCAAAGAGACC
-3’,S i x 1r e v e r s e :5 ’- GGAGAGAGTTGATTCTGCTT
GTT -3’; b3Integrin forward: 5’- GGGCA GTGTCATG
TTGGTAG -3’, b3 Integrin reverse: 5’- CAGCCCCAAA
GAGGGATAAT -3’;P A I - 1f o r w a r d :5 ’- TCCAGCA
GCTGAATTCCTG -3’,P A I - 1r e v e r s e :5 ’-G C T G G A
GACATCTGCATCCT -3’,Z E B 2f o r w a r d :5 ’- AAGC
CAGGGACAGATCAGC-3’,Z E B 2r e v e r s e :5 ’- CCA
CACTCTGTGCATTTGAACT-3’, b-Actin forward: 5’-
CCAACCGCGAGAAGATGA-3’; b-Actin reverse: 5’-
CCAGAGGCGTACAGGGATAG-3’. The assays were
performed using the 1-Step Brilliant
® SYBRII
® Green
QRT-PCR Master Mix Kit (Stratagene) containing
200 nM forward primer, 200 nM reverse primer, and
100 ng total RNA. The conditions for cDNA synthesis
and target mRNA amplification were performed as fol-
lows: 1 cycle of 50°C for 30 min; 1 cycle of 95°C for
10 min; and 35 cycles each of 95°C for 30 s, 55°C for
1 min, and 72°C for 30 s.
Western Blot Analysis
Treated cells were washed twice with cold PBS and
100 μL of cold lysis buffer [50 mM Tris-HCl, 150 mM
NaCl, 100 mM NaF, 10 mM MgCl2, 0.5% NP40, protease
inhibitor cocktail, and phosphatase inhibitor I and II
(Sigma)] was added directly to the plate. The cells were
incubated for 30 minutes at 4°C on a shaker and then
harvested using a rubber policeman. The lysates were
passed 4 times through a 26 gauge syringe, kept on ice
for 30 minutes, and then centrifuged for 20 minutes at
12,000 rpms at 4°C. The supernatant was transferred to
a new tube and the protein was quantified utilizing
the BCA™ Protein Assay Kit (Pierce, Rockford, IL). A
total of 50 μg of protein was run on a 10% SDS-Page gel
and transferred to a PVDF membrane. The membrane
was blocked for 45 minutes with 5% milk in tris-buffered
saline containing 0.05% Tween-20 (TBS-T). The primary
antibodies used in this study were [Rabbit phospho-ERK1/
2 (Thr202/Tyr204) (1:1000), #4377, Cell Signaling Tech-
n o l o g i e s ,D a n v e r s ,M A ;R a b b i tE R K 1 / 2( 1 : 1 0 0 0 ) ,s c - 9 4 ,
Santa Cruz Biotechnology, Santa Cruz, CA; Rabbit b-actin
(1:2000), ab8227, Abcam, Cambridge, MA] incubated
overnight at 4°C. The secondary antibody [goat anti-rabbit
IgG-HRP (Santa Cruz Biotechnology) was applied (1:5000)
and incubated for 45 minutes at room temperature. The
blot was washed and developed using a Western Blot
Luminol Reagent (Santa Cruz Biotechnology).
Transwell Migration Assays
Treated cells were trypsinized, centrifuged at 1,000 × g
for 3 min, and brought to a concentration of 1 ×
10
6 cells/ml in serum-free media. 5 × 10
5 cells/well
were seeded in serum free media (containing DMSO or
10 μM LY364947) either in BD BioCoat control cham-
bers (BD Biosciences) above media containing 10% FBS.
Following a 22-hour incubation, chambers were
removed and cells were fixed for 10 min in 10% forma-
lin, stained for 10 min with 10% Crystal Violet, and
rinsed 3X with dH20. Non-migrating were removed
from the upper surface of the membrane by scrubbing
the insert with a cotton tipped swab moistened with 1X
PBS. The insert was then removed from the chamber
with a scalpel, and mounted on a microscope slide in
Cytoseal™XYL mounting medium (Richard-Allan Scien-
tific). Images were captured with an Olympic BX41 light
microscope using SPOTSOFTWARE (Diagnostic Instru-
ments, Inc, Sterling Heights, MI).
Results
SFRP1 loss stimulates the TGFb signaling pathway
Our initial screen of genes affected by SFRP1 loss in
HMECs identified several upregulated genes within the
TGF-b pathway, which suggested that there may be
an alteration in this signaling pathway in TERT-
siSFRP1 cells (Additional File 1). The increased expres-
sion of upstream regulators of TGF-b signaling included
the TGF-b2 ligand as well as Six1, a homeodomain pro-
tein which promotes TGF-b-mediated EMT [20]. Also,
mRNA levels of ZEB2 were elevated in TERT-
siSFRP1 cells and ZEB2 has been shown to interact with
downstream mediators of TGF-b signaling (Smads) and
has been suggested to be involved in TGF-b-induced
EMT [21]. Finally, Integrin b3 and plasminogin activator
inhibitor type-1 (PAI-1), which are transcriptional tar-
gets of the TGF-b signaling pathway [22,23], were signif-
icantly up-regulated in response to loss of SFRP1. Taken
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signaling is augmented in TERT-siSFRP1 cells. First,
TERT-pSUPER and TERT-siSFRP1 cells were trans-
fected with a TGF-b reporter construct, CAGA-Luc,
and grown overnight in the presence or absence of
TGF-b1. Twenty-four hours after transfection, luciferase
activity was measured and we found that TERT-
siSFRP1 cells exhibited a significant increase in relative
luciferase activity when grown in the presence of the
TGF-b1 ligand (Figure 1). Next, we sought to determine
whether endogenous TGF-b responsive gene expression is
altered in response to SFRP1 loss. Since both Integrin
b3 and PAI-1 are transcriptionally upregulated in response
to TGF-b1 treatment, we decided to measure the mRNA
expression of these genes in TERT-siSFRP1 cells and the
effect of TGF-b1 treatment on these genes. The expression
of both Integrin b3 and PAI-1 was significantly up-regu-
lated in response to SFRP1 loss and treatment with TGF-
b1 further increases the mRNA expression levels of Integ-
rin b3 in TERT-siSFRP1 cells (Figure 2A, upper panels).
To verify that the expression of these TGF-b targets was
due to aberrant TGF-b signaling in response to
SFRP1 down-regulation, cells were treated with a TGF-b
receptor (TGF-bR1) specific inhibitor (LY364957) and
gene expression was again analyzed by way of real-time
PCR. Our results clearly demonstrate that the expression
of both Integrin b3 and PAI-1 is significantly inhibited in
response to LY364947 treatment in TERT-siSFRP1 cells
(Figure 2B, lower panels).
Loss of SFRP1 increases the phosphorylation of
ERK1/2 through TGF-b signaling
TGF-b signaling has been shown to increase the phos-
phorylation of ERK1/2 so we first sought to establish
whether of ERK1/2 is phosphorylated in response to
loss of SFRP1. Western blot analysis revealed that
TERT-siSFRP1 cells express higher levels of phosphory-
lated ERK1/2 and treatment with an ERK1/2 specific
inhibitor (U0126) confirmed that ERK1/2 activation was
through a Mek-dependent phosphorylation (Figure 3A,
upper left panel). We next wanted to determine whether
treatment with TGF-b1 could induce the phosphoryla-
tion of ERK1/2 in immortalized HMECs and whether
the phosphorylation of ERK1/2 we observe in the
TERT-siSFRP1 cells could be blocked by antagonizing
the TGF-bR with LY364947. Our results illustrate that
in our control cell line (TERT-pSUPER), ERK1/2
phosphorylation was observed in response to TGF-
b1 treatment and blocking the TGF-bR abrogated this
activation. As expected, ERK1/2 was constitutively phos-
phorylated in TERT-siSFRP1 cells even in the absence
of TGF-b1 treatment (Figure 3B, upper right panel).
Interestingly, treatment with LY364947 reduced the
levels of ERK1/2 phosphorylation, independent of TGF-
b1 stimulation, which supports the notion that these
cells are not only more sensitive to TGF-b,b u tt h a t
TGF-b signaling pathway is also aberrantly activated in
TERT-siSFRP1 cells.
TGF-b has been demonstrated to play an important
role in activating cellular migration in part by way of
ERK1/2 signaling in breast cancer cells [24]. Considering
that ERK1/2 is phosphorylated and TGF-b signaling is
misregulated in TERT-siFRP1 cells, we tested the
hypothesis that the increase in cellular migration
observed in response to SFRP1 loss may be partially due
to these two aforementioned observations. First, a simple
scratch wound assay revealed that TERT-siSFRP1 cells
treated with LY364947 were much less motile then cells
treated with vehicle (data not shown). These results were
confirmed using migration chamber assays. Control cells
(TERT-pSUPER) and TERT-siSFRP1 cells were plated in
BD BioCoat™ control chambers and the cells capable of
migrating through the 8 μm pore towards a chemoattrac-
tant were stained with 10% crystal violet and quantified.
We clearly show that by blocking the TGF-b pathway
with LY364947, we could significantly hinder the migra-
tory action of TERT-siSFRP1 cells (Figure 3C, lower
panel)
TGF-b signaling is mediated by ZEB2 in TERT-siSFRP1 cells
ZEB2 was originally characterized as a Smad interacting
protein (SIP) and regulator of TGF-b signaling [17]. We
therefore hypothesized that the significant up-regulation
of ZEB2 that occurs in response to SFRP1 loss may par-
tially explain the enhanced constitutive activation of
TGF-b signaling in TERT-siSFRP1 cells. To test this
hypothesis, we knocked-down ZEB2 using siRNAs and
real-time PCR analysis verified that there was a significant
Figure 1 Loss of SFRP1 enhances TGF-b signaling activity. TERT-
pSUPER and TERT-siSFRP1 cells were transfected with the CAGA-Luc
and CMV-Renilla reporter vectors and relative luciferase activity was
measured after an overnight incubation in the presence or absence
of the 2.5 ng/ml TGF-b1. Bars represent mean ± SEM of relative
luciferase activity (firefly luciferase activity/renilla luciferase activity)
normalized to the relative luciferase activity in TERT-pSUPER cells
treated with vehicle. ***p < 0.001 [significantly different from
corresponding TERT-pSUPER cell line using students’s t-test].
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upper left panel). Next, TERT-siSFRP1 cells were trans-
fected with control or ZEB2 specific siRNAs, as well as the
CAGA-Luc reporter vector, and grown overnight in the
presence or absence of TGF-b1. Twenty-four hours after
transfection, the luciferase activity was measured. We
found that when ZEB2 levels were repressed in TERT-
siSFRP1 cells, relative CAGA-luciferase activity was signifi-
cantly hampered in response to TGF-b1 treatment
(Figure 4B, upper right panel). In addition, real-time PCR
analysis confirmed that the mRNA expression of TGF-b
responsive genes, including Integrin b3 and PAI-1, was sig-
nificantly down-regulated when ZEB2 is knocked down in
TERT-siSFRP1 cells (Figure 4C, lower panel). Finally, we
wished to determine whether similar to TGF-bR inhibi-
tion, ZEB2 blockade could inhibit cellular migration. Fol-
lowing transfection with control or ZEB2 specific siRNAs,
a migration assay using BD BioCoat™ control chambers
was carried out and revealed that ZEB2 knockdown
reduced the number of TERT-siSFRP1 cells that were cap-
able of migrating through the 8 μm pore towards the che-
moattractant (Figure 5A, upper panel). The number of
cells was quantified and we confirmed that in response to
ZEB2 down-regulation, cellular migration was significantly
reduced (Figure 5B, lower panel).
Discussion
The present study indicates that loss of SFRP1 expression
allows an immortalized non-malignant cell line (76N
TERT) to acquire sensitivity to TGF-b signaling due to
inappropriate activation of ZEB2. These cells with
SFRP1 knocked down (TERT-siSFRP1) display a significant
increase in both exogeneous and endogenous TGF-b tran-
scriptional targets, which is further enhanced by the pre-
sence of TGFb. Moreover, ERK1/2 phosphorylation is
increased in TERT-siSFRP1 cells by way of enhanced
TGF-b signaling. The TGF-b-mediated activation partially
explains the migratory phenotype of TERT-siSFRP1 cells
considering that when the TGF-b pathway is blocked with
LY364947, cellular migration is significantly hindered. Based
on our ZEB2 knockdown experiments, the significant up-
regulation of ZEB2 that occurs in response to SFRP1 loss
partially explains the mechanism by which TGF-b signaling
is mis-regulated in TERT-siSFRP1 cells. We clearly show
that exogeneous and endogenous TGF-b transcriptional tar-
gets, which are upregulated in TERT-siSFRP1 cells, are
repressed when the levels of ZEB2 mRNA are decreased.
Finally, we found that similar to TGF-bR inhibition,
ZEB2 blockade inhibits cellular migration.
Previously, we demonstrated that the Wnt/b-catenin
signaling pathway is significantly up-regulated in
Figure 2 TGF-b responsive gene expression is augmented in response to SFRP1 loss. After an overnight treatment with 2.5 ng/ml TGF-b1
(A), or an overnight treatment with 10 μM LY364947 (B), total RNA was isolated from three separate harvests for real-time PCR analysis of b3
Integrin and PAI-1. All real-time PCR results are from two separate experiments performed in triplicate and results were normalized to
amplification of b-actin mRNA. Bars represent mean ± SEM and are expressed as fold change with respect to TERT-pSUPER cells. *p < 0.05,
**p < 0.01, ***p < 0.001 (significantly different from indicated data set using student’s t-test).
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mental processes and patterning events require inputs
from both Wnt and TGF-b family members [25,26].
Work by Labbe et. al [27] identified a cohort of genes
that are dually affected by both Wnt and TGF-b ligands.
Interestingly, several of these genes are elevated in
tumors derived from the MMTV-Wnt-1 mouse model
and when TGF-b signaling is blocked by overexpression
of the dominant negative type II TGF-b receptor, the
expression these genes is not only lost, but there is an
increase in tumor-free survival. These data indicate that
crosstalk between the Wnt signaling pathway and TGF-
b cooperate to promote tumor development. Mechanis-
tically, this phenomenon may be partially explained by
the finding that Wnt mediated b-catenin translocation
results in association with the Lef1 transcription factor,
which has been shown to interact with Smad4 and up-
regulate TGF-b targets [28]. Thus, the Wnt signaling
status of TERT-siSFRP1 likely predicts the TGF-b activ-
ity we report here.
The data presented in this article clearly illustrate that
TERT-siSFRP1 cells are significantly more sensitive to
TGF-b signaling. Not only does TGF-b p l a yad u a lr o l e
in tumor progression, but it also known to play an
important role in human embryonic stem cells [29].
Considering that TERT-siSFRP1 cells exhibit cancer
initiating-cell-like characteristics and display a CD44
high/
CD24
low cell surface marker expression pattern [16,30],
our current results are fully consistent with previously
published research by Shipitsin et. al showing that
Figure 3 Loss of SFRP1 increases TGF-b mediated ERK1/2 acivation and migration. TERT-pSUPER and TERT-siSFRP1 cells were serum
starved overnight and treated with 5 μM U0126 (A) or 2.5 ng/ml TGF-b1 and/or 10 μM LY364947 (B). Cell lysates were analyzed for phospho-
ERK1/2, ERK1/2, and Actin protein expression by western blot (A-B). TERT-pSUPER and TERT-siSFRP1 cells were plated in BD BioCoat™ control
inserts and the cells capable of migrating through the 8 μm pore towards a chemoattractant were stained with 10% crystal violet and counted.
Images were captured at 10X magnification (C). Experiments were repeated the number of cells within a representative 10X field from each
experiment were counted and bars represent mean ± SEM cell number (D). *p < 0.05, (significantly different from vehicle treated cells using a
student’s t-test).
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high/CD24
low cells are more responsive to TGF-b
and can be specifically targeted by TGF-bR inhibition
[31]. These data support the notion that the Wnt/b-
catenin and TGFb signaling pathways are feeding into
each other and facilitating the development of aggressive
tumor characteristics.
Downstream transcriptional targets of TGF-b,i n c l u d -
ing Integrin b3 and PAI-1 are also significantly more
sensitive to TGF-b when the expression of SFRP1 is
knocked down. The finding that Integrin b3 is upregu-
lated in TERT-siSFRP1 partially explains the migratory
and invasive characteristics exhibited by these cells.
When breast cancer cells express Integrin b3, their inva-
siveness is enhanced in vivo [32]. Also, it has previously
been shown that the induction of Integrin b3 expression
during mammary tumorigenesis correlates with the
development of metastases and that when Integrin b3 is
antagonized, breast cancer cell invasion abolished [33].
Consistent with what we present in this current report,
Galliher et. al demonstrate that the expression of Integ-
rin b3 alters the response of mammary epithelial cells to
TGF-b-mediated EMT [33]. Interestingly, small
Figure 4 Knockdown of ZEB2 partially blocks TGF-b signaling in TERT-siSFRP1 cells. Stealth RNAi™ siRNA negative controls (62.5 nM) were
transfected into TERT-pSUPER and TERT-siSFRP1 cells [TERT-pSUPER (control) and TERT-siSFRP1 (control)] and ZEB2 Stealth RNAi™ siRNA (62.5
nM) was transfected into TERT-siSFRP1 cells [TERT-siSFRP1 (siZEB2)]. Forty-eight hours after transfection, total RNA was isolated from each cell line
for real-time PCR analysis. The levels of ZEB2 mRNA (A) b3 Integrin mRNA and PAI-1 mRNA (C) were normalized to amplification of b-actin
mRNA, which was performed in parallel wells for each cell line. Bars represent mean ± SEM and are expressed as relative expression of TERT-
pSUPER (control) cells. *p < 0.05, ***p < 0.001 (significantly different from TERT-pSUPER (control) cell line using Bonferroni’s t-test following 1-way
ANOVA). (B) TERT-siSFRP1 cells were transfected with either a Stealth RNAi™ siRNA negative control (62.5 nM) or ZEB2 Stealth RNAi™ siRNA
(62.5 nM) and CAGA-Luc plus CMV-Renilla reporter vectors. The relative luciferase activity was measured after an overnight incubation in the
presence or absence of the 2.5 ng/ml TGF-b1. Bars represent mean ± SEM of relative luciferase activity (firefly luciferase activity/renilla luciferase
activity) normalized to the relative luciferase activity in TERT-siSFRP1 (control) cells treated with vehicle. ***p < 0.001 [significantly different from
corresponding TERT-siSFRP1 (control) cell line using students’s t-test].
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developed as anti-cancer therapeutics [34]. Likewise,
PAI-1 is also a proposed anti-cancer target [35]. Several
components of the plasminogen activation system,
including PA1-1, are implicated in tissue remodeling
associated with both physiological and pathologic pro-
cesses such as wound healing, mammary gland involu-
tion, angiogenesis, and cancer invasion [36]. Specifically,
PAI-1 promotes tumor growth, angiogenesis, and metas-
tasis [37-40]. Our findings show that by reducing
ZEB2 levels, we can subsequently reduce the expression
of both Integrin b3 and PAI-1. Taken together, these
data suggest that ZEB2 is a central transcriptional regu-
lator, which controls gene expression necessary for the
progression of metastatic cancer. Elloul et. al. [41] ana-
lyzed the expression of ZEB2 as well as other transcrip-
tional repressors of E-cadherin in ovarian and breast
carcinoma effusions and revealed that elevated mRNA
levels of ZEB2 are a predictor of poor survival [41].
Thus, ZEB2 may be an important anti-cancer therapeu-
tic target.
In order to establish whether TGF-b signaling elicits a
direct physiological consequence when SFRP1 is down-
regulated, we measured activated ERK1/2 levels and the
migratory action of in TERT-siSFRP1 cells in response
to TGF-bR inhibition. As hypothesized, when cells were
treated with LY364947, ERK1/2 phosphorylation and
cellular migration were drastically reduced. Our results
are consistent with previous research which has shown
that TGF-b signaling mediates the cellular migration of
breast cancer cells by several pathways including ERK1/
2 activation [42]. Interestingly, the mechanism by which
TGF-b phosphorylates ERK1/2 is independent of
Smad4, as evidenced by TGF-b induced phosphorylation
of ERK1/2 in the Smad4 deficient MDA-MB-468 cell
line [24]. Our data would agree with this observation.
K n o c kd o w no fZ E B 2d i dn o ta f f e c tt h el e v e l so fp h o s -
phorylated ERK1/2 (data not shown), however inhibition
of the TGF-bR did affect the ERK1/2 phosphorylation
observed in TERT-siSFRP1 suggesting that loss of
ZEB2 affects the canonical TGFb-Smad pathway, but
not other TGF-b initiated pathways. Alternatively, the
phosphorylation of ERK1/2 in TERT-siSFRP1 cells may
require input from multiple signaling pathways. Since
ZEB2 is likely augmenting TGF-b signaling by way of its
Smad interacting domain, the mechanisms by which the
TGF-b pathway affects cellular migration in TERT-
siSFRP1 cells seems to involve both Smad-independent
(ERK1/2) and Smad-dependent (ZEB2) actions.
It has been suggested that overexpression of
ZEB2 plays a putative role in oncogenic transformation
since it was identified in a large-scale screen for cancer
related genes [43]. Data illustrating that high levels of
ZEB2 are expressed in migratory breast cancer cell lines
(MDA-MB-231 and MDA-MB-435S1) but not in breast
cancer cells with a more epithelial/less migratory pheno-
type (MCF7/AZ) [44] supports our finding that
ZEB2 repression hampers the cellular migration. It is
thought that the mechanism by which ZEB2 induces
EMT is by its ability to repress the epithelial cell junction
protein E-cadherin and induce the mesenchymal marker,
vimentin, in breast cancer cell lines [45]. However, the
decrease in cellular migration that occurs in response to
ZEB2 down-regulation in TERT-siSFRP1 is independent
of E-cadherin and vimentin, as the mRNA levels of these
genes are only marginally affected by ZEB2 knockdown
(data not shown). The down-regulation of E-cadherin in
TERT-siSFRP1 cells is likely due to the misregulation of
a combination of E-cadherin transcriptional factors
including ZEB1, Twist, Snail, and Slug. The expression of
vimentin may be mediated by b-catenin in TERT-
Figure 5 Knockdown of ZEB2 diminishes the migratory
phenotype of TERT-siSFRP1 cells. Stealth RNAi™ siRNA negative
controls (62.5 nM) were transfected into TERT-pSUPER and TERT-
siSFRP1 cells and ZEB2 Stealth RNAi™ siRNA (62.5 nM) was
transfected into TERT-siSFRP1 cells. After 24 hours, cells were lifted
from culture dishes and plated in BD BioCoat™ control inserts and
the cells capable of migrating through the 8 μm pore towards a
chemoattractant were stained with 10% crystal violet and counted.
Images were captured at 10X magnification (A). Experiments were
repeated the number of cells within a representative 10X field from
each experiment were counted and bars represent mean ± SEM cell
number (B). *p < 0.05 (significantly different from TERT-pSUPER
(control) cell line using Bonferroni’s t-test following 1-way ANOVA).
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in breast cancer cells [46] and b-catenin activity is
enhanced in TERT-siFRP1 cells [16]. Taken together, this
research suggests that a reduction of SFRP1 can sensitize
immortalized mammary epithelial cells to enhanced
migration through an increased activation and sensitivity
of the TGF-b signaling pathway.
Conclusions
This is the first report to suggest that the loss of a Wnt
signaling antagonist, SFRP1, plays a direct role in TGF-
b-mediated signaling and TGF-b-mediated-cellular
migration. Given our results, the crosstalk that occurs
between the Wnt/b-catenin and TGFb signaling path-
ways seems to be in part synchronized by SFRP1.
Experiments to elucidate whether TERT-siSFRP1 cells
are tumorigenic in vivo and how TGF-b targets are
affected by the paracrine signals elicited are ongoing. In
addition, this work described here is the first to demon-
strate TGF-b sensitivity can be partially ameliorated by
blocking the expression of ZEB2, a key transcription fac-
tor that regulates the progression of tumor cell metasta-
sis. Hence, ZEB2 may be an excellent anti-cancer
therapeutic target.
Additional material
Additional File 1: Genes associated with the TGF-b signaling
pathway are up-regulated in response to SFRP1 down-regulation.
Total RNA was isolated from three separate harvests for real-time PCR
analysis of genes involved in the TGF-b signaling pathway. All real-time
PCR results are from two separate experiments performed in triplicate
and results were normalized to amplification of b-actin mRNA. Bars
represent mean ± SEM and are expressed a fold change with respect to
TERT-pSUPER cells. **p < 0.01, ***p < 0.001 (significantly different from
corresponding TERT-pSUPER cell line using students’s t-test).
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